A bad week for dementia research just got worse after Axovant embarrassingly admitted it a major error in its trial results and yet another trial failure – this time involving Lundbeck’s dr
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas